Investment Rating - The report maintains a "Buy" rating for the company, indicating an expectation that the stock price will exceed the benchmark index by more than 20% in the next 6-12 months [3][5]. Core Views - The company has faced short-term pressure on performance due to adjustments in medical insurance and tax issues, but there is potential for industry concentration to increase, and the company's store count continues to grow steadily. The established membership system and online business provide certain advantages, leading to a positive outlook for future development [3][5][8]. Summary by Sections Financial Performance - In 2024, the company achieved total revenue of RMB 9.283 billion, a year-on-year increase of 2.23%, and a net profit attributable to shareholders of RMB 128 million, a decrease of 69.08%. In Q1 2025, total revenue was RMB 2.294 billion, down 0.85%, with a net profit of RMB 34 million, down 35.85% [3][5][8]. Store Growth and Market Position - The company had a total of 5,486 stores by the end of 2024, with a net increase of 370 stores during the year. The membership base exceeded 26 million, with member consumption accounting for nearly 70% of total sales, supporting stable growth [8]. Industry Outlook - The report highlights that the domestic pharmacy retail industry still has significant room for improvement in concentration, with the current chain rate at 57.81% and a target of 70% by 2025. The top 100 pharmacy retailers accounted for 37.8% of the total retail market, indicating potential for further consolidation [8]. Online Business Development - The company's online business generated RMB 2.586 billion in revenue in 2024, representing 27.85% of total revenue and a year-on-year growth of 19.47%. The third-party O2O platform business contributed RMB 1.106 billion, growing by 33.37% year-on-year [8].

Investment Rating - The investment rating for the company is "Buy" [3][5] - The market price is reported at RMB 23.01 [3] Core Views - The company has faced short-term pressure on performance due to adjustments in medical insurance and tax issues, but there is potential for industry concentration to increase, and the company continues to grow its store count and has established a strong membership system and online business [3][5][8] - The company reported total revenue of RMB 9.283 billion in 2024, a year-on-year increase of 2.23%, and a net profit attributable to shareholders of RMB 128 million, a decrease of 69.08% [3][5] - For Q1 2025, total revenue was RMB 22.94 billion, a decrease of 0.85%, with a net profit of RMB 34 million, down 35.85% year-on-year [3][5] Summary by Relevant Sections Financial Performance - The company’s total revenue for 2024 is projected at RMB 10.32 billion, with a growth rate of 11.2% [7] - The net profit for 2025 is estimated at RMB 263 million, showing a significant recovery from the previous year [7] - The earnings per share (EPS) for 2025 is projected to be RMB 1.70, with a corresponding price-to-earnings (P/E) ratio of 13.5 [5][7] Market Position and Growth Potential - The company has a stable growth in store count, reaching 5,486 stores by 2024, with a net increase of 370 stores [8] - The membership base has exceeded 26 million, with member consumption accounting for nearly 70% of total sales, providing a solid foundation for future growth [8] - The online business generated RMB 25.86 billion in revenue in 2024, representing 27.85% of total revenue, with a year-on-year growth of 19.47% [8] Industry Outlook - The overall concentration in the pharmacy retail industry is expected to increase, with the current chain rate at 57.81%, indicating room for growth towards the 70% target set for 2025 [8] - The top 100 pharmaceutical retailers accounted for 37.8% of the total retail market, suggesting significant potential for market share expansion [8]

Core Viewpoint - The company, Jianzhijia, has shown significant growth in its stock price and is actively expanding its market presence through both self-built and acquired stores, while also focusing on social responsibility and competitive strategies in the healthcare sector [1][2][3]. Group 1: Market Performance - As of May 23, 2025, Jianzhijia's stock closed at 23.01 yuan, a 9.83% increase from the previous week [1]. - The company reached a market capitalization of 3.556 billion yuan, ranking 22nd in the pharmaceutical commercial sector and 3715th in the overall A-share market [1]. Group 2: Store Expansion Strategy - In 2024, Jianzhijia opened 314 self-built stores and acquired 122 stores, resulting in a net increase of 370 stores after closing 66 [2][4]. - The company plans to adapt its expansion strategy based on regional market conditions and policy implementations, emphasizing compliance with national healthcare regulations [2]. Group 3: Social Responsibility Initiatives - Jianzhijia has created approximately 21,000 jobs, focusing on providing opportunities for women and marginalized groups [1]. - The company has engaged in various health education and community support activities, including free health monitoring for over 4 million chronic disease members and significant contributions to public health initiatives [1][4]. Group 4: Competitive Positioning - The company views third-party platforms as partners rather than competitors, leveraging them for data and logistics services to enhance customer reach [3]. - Jianzhijia aims to differentiate itself through unique product offerings, professional services, and brand positioning to maintain a competitive edge in the market [3][4]. Group 5: Corporate Governance - The 2024 annual shareholders' meeting was held on May 21, 2025, with 153 shareholders present, representing 53.24% of the voting shares [5]. - The meeting approved ten resolutions, including financial reports and the appointment of auditing firms, confirming compliance with legal and regulatory standards [5].

Core Viewpoint - The competition among major platforms like Ele.me, JD.com, and Meituan in the food delivery sector has expanded into the pharmaceutical category, leading to a significant rise in the instant retail of medicines, with platforms investing in traffic resources, supply chains, and innovative marketing strategies [1][4]. Group 1: Market Dynamics - The instant retail of pharmaceuticals is experiencing rapid growth, becoming a crucial part of the outpatient pharmaceutical retail market [1][4]. - JD Health's "Buy Medicine in Seconds" feature has seen a threefold increase in order volume due to enhanced traffic resources [4][6]. - The instant retail sector is evolving from high-frequency to low-frequency demand, now covering a full range of categories, including pharmaceuticals [5][6]. Group 2: Platform Strategies - JD.com has prominently featured "24h Delivery of Medicines" on its app, enhancing visibility and traffic for its instant retail services [3][4]. - Meituan has launched its instant retail brand "Meituan Flash Purchase," further intensifying competition in the pharmaceutical retail space [4][6]. - Taobao's instant retail service has been upgraded to "Taobao Flash Purchase," which includes a significant category for purchasing medicines [3][4]. Group 3: Industry Trends - The transformation of physical pharmacies is driving the adoption of instant retail, as many pharmacies are closing, leading to a competitive environment where digital solutions are essential [7][8]. - The integration of online medical services with instant retail is creating a comprehensive service model for users, enhancing the purchasing experience [7][8]. - The collaboration among platforms, pharmaceutical companies, and pharmacies is deepening, allowing for more effective marketing and sales strategies [8][10]. Group 4: Financial Performance - One Heart Hall's new retail segment saw a 47.6% year-on-year increase in revenue, with the O2O instant retail channel contributing 78.2% [15][16]. - Yifeng Pharmacy reported online sales of 2.127 billion yuan in 2024, with 1.721 billion yuan coming from O2O, accounting for 80.9% of total online sales [16][17]. - The overall trend indicates that if online medical insurance is fully opened, the share of instant retail in physical pharmacies could rise to 32.1% by 2030 [16][17]. Group 5: Future Outlook - The competition for instant retail in pharmaceuticals among major platforms is expected to continue, with Douyin's unique position in social media marketing presenting both opportunities and challenges [18]. - The penetration of instant retail in lower-tier markets is anticipated to grow, making it a significant growth driver in the outpatient pharmaceutical retail market [18].

Meeting Overview - The annual general meeting of shareholders was held on May 21, 2025, at the company's headquarters in Kunming, Yunnan Province [2] - The meeting was convened by the board of directors and chaired by the chairman, Mr. Lan Bo, in compliance with the Company Law and the company's articles of association [2] Attendance and Voting - All 7 current directors and 3 supervisors attended the meeting, along with the board secretary and the general manager [3] - There were no rejected resolutions during the meeting [2] Resolutions Passed - The following resolutions were approved: - 2024 Annual Board Work Report [3] - 2024 Annual Supervisory Work Report [3] - 2024 Annual Independent Director Work Report [4] - 2024 Financial Settlement Report [4] - 2025 Financial Budget Plan [4] - 2024 Profit Distribution Plan [4] - Approval of the 2024 Annual Report and its summary [4] - Reappointment of the auditing firm for 2025 [4] - Approval for the company and its subsidiaries to apply for comprehensive credit lines and provide guarantees [4] - Approval of the estimated related party transactions for 2025 [5] Legal Verification - The meeting was witnessed by Beijing Deheng (Kunming) Law Firm, confirming that the meeting's convening, attendance, and voting procedures complied with legal and regulatory requirements [5]

Core Viewpoint - The retail pharmacy industry in China is undergoing significant challenges, with a trend of store closures and a shift from aggressive expansion to a focus on quality and efficiency [3][4][10]. Group 1: Store Closures and Industry Trends - Major retail pharmacy chains, including Lao Bai Xing, Yi Feng Pharmacy, and Yi Xin Tang, have reported a continued strategy of closing underperforming stores while slowing down expansion efforts [3][4]. - In Q1 2025, Lao Bai Xing and Shu Yu Ping Min closed 161 and 86 stores respectively, while Yi Feng Pharmacy opened 94 stores but closed 84 [3][7]. - The overall closure rate in the retail pharmacy sector reached 5.7% in 2024, with over 39,000 stores shutting down [4][11]. Group 2: Financial Performance - Yi Feng Pharmacy reported Q1 2025 revenue of 600.9 million yuan, a year-on-year increase of 0.64%, while its net profit grew by 10.51% [7]. - In contrast, Lao Bai Xing, Yi Xin Tang, and Jian Zhi Jia experienced revenue declines of 1.88%, 6.53%, and 0.85% respectively in Q1 2025 [7][8]. - The financial performance of many listed pharmacy chains has shown a decline in both revenue and profit, indicating a challenging market environment [6][8]. Group 3: Market Dynamics and Future Outlook - The retail pharmacy industry is experiencing a consolidation phase, driven by increased market concentration and regulatory pressures [10][14]. - The shift from rapid expansion to a focus on closing unprofitable stores and improving operational efficiency is becoming a new trend in the industry [10][12]. - Companies are exploring new retail models and diversifying their offerings to adapt to changing market conditions, with some focusing on integrating online and offline sales [14][15].

Group 1 - The law firm Beijing DeHeng (Kunming) has provided legal opinions regarding the annual shareholders' meeting of Jianzhijia Pharmaceutical Chain Group Co., Ltd. [1] - The shareholders' meeting is scheduled for May 21, 2025, and the notice was published more than 20 days prior in various media outlets [2] - A total of 153 shareholders attended the meeting, representing 21,624,173 shares or 13.99% of the voting shares, while 147 shareholders participated via online voting, representing 60,662,057 shares or 39.25% of the voting shares [2] Group 2 - The meeting was presided over by Chairman Lan Bo and complied with legal and regulatory requirements [2] - The agenda included ten proposals, such as the 2024 annual financial report and the 2025 budget plan, which were approved through a combination of on-site and online voting [2] - The law firm concluded that the meeting's procedures, shareholder qualifications, and voting results were in accordance with legal standards and the company's articles of association [3]

Core Viewpoint - The retail pharmacy industry in China is facing significant challenges, leading to a wave of store closures and a shift in focus from rapid expansion to improving operational efficiency and quality [1][6][8]. Group 1: Store Closures and Expansion Strategies - Major retail pharmacy chains, including Lao Bai Xing, Yi Feng Pharmacy, and Yi Xin Tang, are continuing to close underperforming stores while slowing down their expansion efforts [1][4]. - In Q1 2025, Lao Bai Xing closed 161 stores and opened 24, while Yi Feng Pharmacy opened 94 stores (26 self-built and 68 franchises) but closed 84 [1][4]. - The overall closure rate for retail pharmacies reached 5.7% in 2024, with over 39,000 stores shutting down [1][6]. Group 2: Financial Performance - Financial reports for Q1 2025 show a mixed performance among major chains, with Lao Bai Xing, Yi Xin Tang, and Jian Zhi Jia experiencing revenue and profit declines [3][4]. - Yi Feng Pharmacy reported a revenue of 6.009 billion yuan, up 0.64% year-on-year, and a net profit of 449 million yuan, up 10.51% [3][4]. - Dazheng Lin achieved a revenue of 6.956 billion yuan, up 3.02%, and a net profit of 460 million yuan, up 15.45% [3][4]. Group 3: Industry Trends and Challenges - The retail pharmacy sector is undergoing a deep transformation, moving from aggressive expansion to a focus on quality and efficiency due to market saturation and increased regulatory scrutiny [6][8]. - The number of pharmacies in China increased from 524,000 in 2019 to 667,000 in 2023, leading to structural oversupply [8][9]. - Industry experts predict that around 20% of small pharmacies may be eliminated, further increasing market concentration [8]. Group 4: New Retail Strategies - Leading chains are integrating online and offline operations to adapt to changing market dynamics, with Yi Feng Pharmacy reporting significant online sales growth [9][10]. - Dazheng Lin is focusing on building a prescription transfer system and enhancing professional service capabilities to differentiate itself in a competitive landscape [9][10]. - Yi Xin Tang is exploring diversification into non-pharmaceutical products and new business models, such as combining pharmacies with convenience stores [10].

北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司 2024 年年度股东会的 法律意见 北京德恒（昆明）律师事务所 Beijing DeHeng Law Offices (KunMing) 云南省昆明市西山区西园路 126 号"融城优郡"B5 幢 3、4 层 电话（传真）：0871-63172192 邮编: 650034 北京德恒（昆明）律师事务所 关于健之佳医药连锁集团股份有限公司 根据贵公司提供的有关资料及公开披露的信息，表明贵公司已于2025年4月 28日召开了董事会会议，作出了关于召开本次股东会的决议，并于2025年4月29 日在《中国证券报》《上海证券报》《证券时报》《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn）等媒体刊登了召开本次股东会的通知。 本次股东会现场会议于2025年5月21日13:30在云南省昆明市盘龙区联盟街 道旗营街10号健之佳总部14楼会议室召开，会议召开时间与通知公告时间间隔20 天以上，会议召开的具体时间、地点和审议事项也与公告内容一致。 本次股东会由董事长蓝波先生主持，符合法律、法规及贵公司《章程》的规 定。 二、关于出席本次股东会 ...

健之佳医药连锁集团股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：605266 证券简称：健之佳 公告编号：2025-033 | 1、出席会议的股东和代理人人数 | 153 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 82,286,230 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 53.2449 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次临时股东会由公司董事会召集，公司董事长蓝波先生主持，本次股东会 的召集、召开及表决方式符合《中华人民共和国公司法》等法律、法规及规范性 文件及《公司章程》的有关规定。 (一) 股东大会召开的时间：2025 年 5 月 21 日 (二) 股东大会召开的地点：云南省昆明市盘龙区联盟街道旗营街 10 号健之佳 总部 14 楼会议室 (三) ...